2017 American Oncology Society of Clinical Annual Meeting
August 2017 Vol 8, No 8 | August 3, 2017
As the cost of cancer care continues to rise, it’s not just the patients’ finances that are affected. Recent research has linked high out-of-pocket costs to nonadherence and early discontinuation of treatment.
August 2017 Vol 8, No 8 | August 3, 2017
The PARP inhibitor olaparib significantly improved progression-free survival (PFS) compared with standard chemotherapy in women with HER2-negative metastatic breast cancer with a germline BRCA mutation. Disease progression was delayed by about 3 months with olaparib in the multinational, randomized, open-label phase 3 study known as OlympiAD, reported Mark E. Robson, MD, at the 2017 ASCO Annual Meeting.
August 2017 Vol 8, No 8 | August 3, 2017
In the SARC028 phase 2 multicenter trial, reported at the 2017 ASCO Annual Meeting, pembrolizumab achieved encouraging responses in soft tissue sarcoma, especially undifferentiated pleomorphic sarcoma (UPS) and liposarcoma.
August 2017 Vol 8, No 8 | August 3, 2017
Oral cediranib, an investigational VEGF inhibitor, in combination with a PARP or chemotherapy inhibitor, appears to have a survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to data from 2 studies presented at the 2017 ASCO Annual Meeting.
Results 1 - 5 of 5
